The pharmaceutical company Reig Jofre, a member of CATALONIA.HEALTH, has been selected to receive a €13 million grant from the Centre for the Development of Industrial Technology (CDTI). This funding stems from the company’s participation as an associated member in the first European IPCEI health project, Med4Cure.
The grant is part of the Strategic Project for Economic Recovery and Transformation in Advanced Healthcare (PERTE for Health) and represents more than 50% of the total value of the submitted project, highlighting its strong alignment with the strategic objectives of the program. IPCEI Med4Cure is a major European initiative aimed at strengthening Europe’s health sovereignty by boosting industrial and technological capabilities across the entire pharmaceutical value chain, from research and development to manufacturing and distribution.
Within this framework, Reig Jofre is leading the EMINTECH project, a €25 million strategic initiative running from 2023 to 2026, aimed at addressing two major global health challenges: antimicrobial resistance (AMR) and rare diseases. The project focuses on the development of advanced therapies, including CAR-T treatments, gene therapy platforms, phage-based solutions to combat multidrug resistance, and recombinant antibody treatments for rare diseases.
Ignasi Biosca, CEO of Reig Jofre, stated: “Reig Jofre’s participation in the IPCEI Med4Cure reflects our commitment to strengthening European healthcare autonomy through innovation that delivers real impact on health. This project enables us to accelerate the integration of scientific, industrial, and technological capabilities in critical areas such as antimicrobial resistance, biotechnology, and advanced therapies for rare diseases. It is undoubtedly a strategic step to consolidate our position as a key partner in the new European pharmaceutical model.”
Comments